Main Article Content

Dr. Kaneriya Maulik
Dr. Smita Trivedi
Dr. Shailee Patel
Dr. Bhutiya Malde
Dr. Parth Jakasaniya


C-Reactive Protein, Pleural Effusion, Exudates, Transudates, Leukocytes


Background and Objectives: Exudative pleural effusion is a common clinical problem with various underlying causes. This study aimed to assess the diagnostic utility of pleural fluid C-reactive protein (CRP) in differentiating between the etiologies of exudative pleural effusions, specifically focusing on tuberculous, malignant, and parapneumonic effusions.

Material and Methods: We enrolled 60 patients with exudative pleural effusion diagnosed through clinico-radiological criteria. Sociodemographic and hematological variables were evaluated across the three etiological groups. Additionally, pleural fluid parameters, including CRP, were measured. The study participants were categorized into groups based on the etiology of their effusions as malignant, parapneumonic and tubercular effusions.

Results:  Tuberculous effusion was the most common etiology in our study, followed by malignant and parapneumonic effusions. Malignant effusions were more prevalent in older age groups and among males. Hematological variables did not show significant differences between the groups. Total leukocyte counts were higher in parapneumonic effusions. Smoking history was more prevalent among patients with malignant effusions. Co-morbid conditions like hypertension and diabetes did not correlate significantly with effusion etiology. Pleural fluid LDH, ADA, and CRP were elevated in tuberculous effusions compared to malignant effusions.

Conclusion: Pleural fluid CRP levels were notably higher in parapneumonic effusions compared to both tuberculous and malignant effusions. Additionally, CRP demonstrated a significant role in distinguishing between parapneumonic and malignant effusions, as well as between tuberculous and malignant effusions. These findings suggest that pleural fluid CRP can serve as a valuable diagnostic marker in the etiological differentiation of exudative pleural effusions, aiding clinicians in prompt and accurate decision-making for patient care.

Abstract 148 | pdf Downloads 83


1. Light R. Disorders of the pleura. In: Harrison's Principles of Internal Medicine. New York, NY: McGraw Hill LLC; 2022. p. 2197–2200.
2. Light R. Clinical manifestations and useful tests. In: Pleural Diseases. Philadelphia, PA: Wolter Kluwer Business; 2013. p. 86–127.
3. Radhakrishnan P, Mathanraj S. Role of pleural fluid C-reactive protein in the aetiological diagnosis of exudative pleural effusion. J Clin Diagn Res. 2020;1:3–7.
4. Yilmaz Turay U, Yildirim Z, Türköz Y, et al. Use of pleural fluid C-reactive protein in diagnosis of pleural effusions. Respir Med. 2000;94:432–435.
5. Watanabe N, Ishii T, Kita N, et al. The usefulness of pleural fluid presepsin, C-reactive protein, and procalcitonin in distinguishing different causes of pleural effusions. BMC Pulm Med. 2018;18:176.
6. Tarn AC, Lapworth R. BTS guidelines for investigation of unilateral pleural effusion in adults. Thorax. 2004;1:358–359.
7. Santotoribio JD, León-Justel A, Delgado-Pecellín C, Guerrero JM. What are the biochemical parameters of pleural fluid that best identify parapneumonic effusions? Ann Clin Biochem. 2009;46:176–177.
8. Manuel Porcel J, Vives M, Esquerda A, Ruiz A. Usefulness of the British Thoracic Society and the American College of Chest Physicians guidelines in predicting pleural drainage of non-purulent parapneumonic effusions. Respir Med. 2006;100:933–937.
9. Falguera M, Carratalà J, Bielsa S, et al. Predictive factors, microbiology, and outcome of patients with parapneumonic effusion. Eur Respir J. 2011;38:1173–1179.
10. Porcel JM, Vives M, Cao G, Bielsa S, Ruiz-González A, Martínez-Iribarren A, Esquerda A. Biomarkers of infection for the differential diagnosis of pleural effusions. Eur Respir J. 2009;34:1383–1389.
11. Porcel JM. Pearls and myths in pleural fluid analysis. Respirology. 2011;16:44–52.
12. Castaño Vidriales JL, Amores Antequera C. Use of pleural fluid C-reactive protein in laboratory diagnosis of pleural effusions. Eur J Med. 1992;1:201–207.
13. Waffa S, ElShimy G, Ghada. Diagnostic value of procalcitonin and CRP in differentiation between some benign and malignant pleural effusions. Egyptian Journal of Chest Diseases and Tuberculosis. 2014;63:923-930.
14. Mona Mansour Ahmed. Cut Off value of pleural fluid CRP in etiological diagnosis of pleural fluid. Egyptian Journal of Chest Diseases and Tuberculosis. 2014;63:617-623.
15. Gabhale S, Pallavi. Usefulness of pleural fluid CRP level in differential diagnosis of Exudative Pleural Effusions - A Pilot Study. International Journal of Clinical Biochemistry and Research. April-June 2015;2(2):97-109.
16. Qiaoying Ji, Bifei Huang. Pleural fluid prealbumin and CRP in differential diagnosis of infectious from malignant pleural effusions. Experimental and Therapeutic Medicine. 2014;7:778-784.
17. Hussein SA, Elhefnawy MY. Relations between serum and pleural fluid biomarkers: a new look at an old concept. Egypt J Bronchol. 2020;14(4).
18. San Jose V, Valdess L. Procalcitonin, CRP, and cell counts in the diagnosis of parapneumonic pleural effusions. Journal Investig Med. 2010;58(8):971-976.
19. Perlat O, Oner Dikenosoy. Acute inflammation biomarkers in pleural effusion. Turkey; 2012(9):15-30.
20. Mona Mansour Ahmed. Cut-off value of pleural fluid CRP in the etiological diagnosis of pleural fluid. Egyptian Journal of Chest Diseases and Tuberculosis. 2014;63:617-623.
21. Porcel JM, Vives M. Distribution of pleural effusion in congestive heart failure. Southern Medical Journal. 2006;99(1):98.
22. Nusarth A, Maithiri. Efficacy of pleural fluid ADA and CRP in early differentiation of pleural effusions. J Evol Med Dent Sci. 2013;2(22):3537-3544.
23. Motoki S, Kiminikho. Pleural fluid ADA level and occult tubercular pleurisy. Ann Thorac Cardiovasc Surg. 2009;15(5):294-296.
24. San Jose VL. Procalcitonin, CRP, and cell counts in the diagnosis of parapneumonic pleural effusions. J Investig Med. 2010 Dec;58(8):971-976.